These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38845248)

  • 21. Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus.
    Bae S; Durand CM; Garonzik-Wang JM; Chow EKH; Kucirka LM; McAdams-DeMarco MA; Massie AB; Al Ammary F; Coresh J; Segev DL
    Transplantation; 2020 Jun; 104(6):1294-1303. PubMed ID: 32433232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
    Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
    Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue Expression of Programmed Cell Death 1 Ligand1 (PD-L1) in Biopsies of Transplant Livers of Pediatric Patients as a Possible Marker of Acute Cellular Rejection.
    Szymanska S; Markiewicz-Kijewska M; Pyzlak M; Karkucinska-Wienckowska A; Ciopinski M; Czubkowski P; Kaliciński P
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute rejection episodes in dog renal allograft recipients receiving cyclosporin A:ATG vs prednisolone.
    Kelly GE; Sheil AG
    Aust N Z J Surg; 1986 Mar; 56(3):251-5. PubMed ID: 3521569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.
    Weinberg OK; Pinkus GC; Ramos-Gonzalez GJ; Agur T; Rodig NM
    Clin Transplant; 2023 Dec; 37(12):e15134. PubMed ID: 37772613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation--a prospective, randomized study.
    Yussim A; Shapira Z
    Transpl Int; 2000; 13 Suppl 1():S293-4. PubMed ID: 11112016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
    Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular mechanisms underlying differential rejection of sequential heart and lung allografts in rats.
    Moller F; Hoyt G; Farfan F; Starnes VA; Clayberger C
    Transplantation; 1993 Mar; 55(3):650-5. PubMed ID: 8456486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary pediatric live-donor-kidney transplant-recipients' outcomes by immunosuppression induction received in the United States.
    Riad S; Jackson S; Chinnakotla S; Verghese P
    Pediatr Transplant; 2021 Aug; 25(5):e13925. PubMed ID: 33333629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
    Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 Gene Polymorphisms on Allograft Rejection in Pediatric Renal Transplant Recipients.
    Akad Dincer S; Sahin FI; Terzi YK; Gulleroglu K; Baskin E; Haberal M
    Exp Clin Transplant; 2023 Apr; 21(4):333-337. PubMed ID: 32799785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of the induction phase of antithymocyte-globulin-induced heart allograft tolerance in the rat.
    Olausson M; Mjörnstedt L; Wramner L; Lindholm L; Söderström T; Brynger H
    Int Arch Allergy Appl Immunol; 1988; 86(2):131-8. PubMed ID: 3292435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 signal on liver dendritic cells is critical for Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice.
    Liu H; Bakthavatsalam R; Meng Z; Li Z; Li W; Perkins JD; Reyes J
    Transplant Proc; 2013 Jun; 45(5):1853-5. PubMed ID: 23769057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection.
    Lipson EJ; Naqvi FF; Loss MJ; Schollenberger MD; Pardoll DM; Moore J; Brennan DC
    Am J Transplant; 2020 Aug; 20(8):2264-2268. PubMed ID: 32185872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes.
    Zhang Z; Sun Z; Fu J; Lin Q; Banu K; Chauhan K; Planoutene M; Wei C; Salem F; Yi Z; Liu R; Cravedi P; Cheng H; Hao K; O'Connell PJ; Ishibe S; Zhang W; Coca SG; Gibson IW; Colvin RB; He JC; Heeger PS; Murphy B; Menon MC
    J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34499625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period.
    Simon T; Opelz G; Weimer R; Wiesel M; Feustel A; Ott RC; Süsal C
    Clin Transplant; 2003 Jun; 17(3):217-24. PubMed ID: 12780671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
    Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
    Front Immunol; 2021; 12():653437. PubMed ID: 34349755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble tumor necrosis factor-receptors are not a useful marker of acute allograft rejection: a study in patients with renal or cardiac allografts.
    Leeuwenberg JF; Froon AH; Vaessen LM; Hoitsma AJ; Abramowicz D; van Hooff JP; Buurman WA
    Transpl Int; 1995; 8(6):459-65. PubMed ID: 8579737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival.
    Shen L; Jin Y; Freeman GJ; Sharpe AH; Dana MR
    J Immunol; 2007 Sep; 179(6):3672-9. PubMed ID: 17785803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.